## Thein Hlaing Oo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4885941/publications.pdf

Version: 2024-02-01

623734 552781 128 976 14 26 g-index citations h-index papers 130 130 130 1420 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Management and Outcomes of Hematological Immune-related Adverse Events: Systematic Review and Meta-analysis. Journal of Immunotherapy, 2022, 45, 13-24.	2.4	10
2	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with nonpancreatic gastrointestinal cancers receiving chemotherapy. Baylor University Medical Center Proceedings, 2022, 35, 1-5.	0.5	0
3	Meta-analysis of randomized controlled trials on primary ambulatory thromboprophylaxis in patients with ovarian cancer receiving chemotherapy. Baylor University Medical Center Proceedings, 2022, 35, 1-5.	0.5	O
4	Thrombotic microangiopathy (TMA) in adult patients with solid tumors: a challenging complication in the era of emerging anticancer therapies. Supportive Care in Cancer, 2022, 30, 8599-8609.	2.2	5
5	Primary ambulatory thromboprophylaxis in patients with pancreatic cancer receiving chemotherapy: hope or hype?. Supportive Care in Cancer, 2022, , .	2.2	O
6	Current Controversies in Inferior Vena Cava Filter Placement: <i>AJR</i> Expert Panel Narrative Review. American Journal of Roentgenology, 2021, 216, 563-569.	2.2	9
7	Secondary erythrocytosis due to hemoglobin San Diego. Baylor University Medical Center Proceedings, 2021, 34, 159-160.	0.5	O
8	The Clinical Applicability of Primary Thromboprophylaxis in Ambulatory Patients With Pancreatic Cancer. Pancreas, 2021, 50, 494-499.	1.1	1
9	Pernicious anemia: Pathophysiology and diagnostic difficulties. Journal of Evidence-Based Medicine, 2021, 14, 161-169.	1.8	16
10	Treatment of catheter-related thrombosis in patients with hematologic malignancies: A Venous thromboEmbolism Network U.S. retrospective cohort study. Thrombosis Research, 2021, 202, 155-161.	1.7	8
11	Risk of pulmonary emboli after removal of an upper extremity central catheter associated with a deep vein thrombosis. Blood Advances, 2021, 5, 2807-2812.	5.2	10
12	Bleeding outcomes in thrombocytopenic acute leukemic patients with venous thromboembolism. EJHaem, 2020, $1,448-456$ .	1.0	3
13	Identifying Hemostatic Thresholds in Cancer Patients Undergoing Coronary Angiography Based on Platelet Count and Thromboelastography. Frontiers in Cardiovascular Medicine, 2020, 7, 9.	2.4	9
14	Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials. Breast Cancer Research and Treatment, 2020, 183, 479-487.	2.5	30
15	Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy. Lung, 2020, 198, 575-579.	3.3	5
16	Gaucher disease type 1 first recognized in an elderly patient with thrombocytopenia and lung adenocarcinoma. Clinical Case Reports (discontinued), 2019, 7, 1804-1805.	0.5	1
17	Direct Oral Anticoagulants in the Prevention and Treatment of Venous Thromboembolism in Patients with Cancer: New Insights from Randomized Controlled Trials. Drugs, 2019, 79, 621-631.	10.9	3
18	Reply to M. Alexander et al Asia-Pacific Journal of Clinical Oncology, 2019, 15, 185-185.	1.1	0

#	Article	IF	Citations
19	Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. American Journal of Hematology, 2019, 94, 563-574.	4.1	51
20	Diamond Lamb wave spin-mechanical resonators with optically coherent nitrogen vacancy centers. Journal of Applied Physics, 2019, 126, .	2.5	15
21	2019 international clinical practice guidelines for the treatment of venous thromboembolism. Lancet Oncology, The, 2019, 20, e655.	10.7	2
22	Acquired amegakaryocytic thrombocytopenia and red cell aplasia in a patient with thymoma progressing to aplastic anemia successfully treated with allogenic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2019, 12, 115-118.	0.9	14
23	Optimal Timing for Removal of an Upper Extremity Central Catheter When Associated with a Deep Vein Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Blood, 2019, 134, 325-325.	1.4	3
24	Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy. Blood, 2019, 134, 3469-3469.	1.4	1
25	Diamond Phononic Crystal Spin-Mechanical Resonators with Spectrally-Stable Nitrogen Vacancy Centers. , 2019, , .		0
26	Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Locally Advanced or Metastatic Lung Cancer (LC) Receiving Chemotherapy. Blood, 2019, 134, 3466-3466.	1.4	0
27	Diagnostic Performance of Heparin-Platelet Factor 4 Antibodies in the Identification of Heparin-Induced Thrombocytopenia in Cancer Population. Blood, 2019, 134, 4896-4896.	1.4	0
28	A Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Gastrointestinal Cancers Receiving Chemotherapy. Blood, 2019, 134, 3679-3679.	1.4	0
29	Updated Meta-Analysis of Randomized Controlled Trials on Primary Ambulatory Thromboprophylaxis (PATP) in Patients with Locally Advanced or Metastatic Lung Cancer Receiving Chemotherapy. Blood, 2019, 134, 2435-2435.	1.4	0
30	Diagnostic difficulties in pernicious anemia. Discovery Medicine, 2019, 28, 247-253.	0.5	8
31	Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center. Journal of Thrombosis and Thrombolysis, 2018, 45, 377-385.	2.1	8
32	Primary thromboprophylaxis (PTP) in ambulatory patients with lung cancer receiving chemotherapy: A systematic review and metaâ€analysis of randomized controlled trials (RCTs). Asia-Pacific Journal of Clinical Oncology, 2018, 14, 210-216.	1.1	20
33	Management of Immune-mediated Cytopenias in the Era of Cancer Immunotherapy: A Report of 4 Cases. Journal of Immunotherapy, 2018, 41, 32-34.	2.4	26
34	Renal cell carcinoma metastasizing to the myeloproliferative bone marrow. Blood Research, 2018, 53, 9.	1.3	0
35	Updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients. Annals of Oncology, 2018, 29, viii606.	1.2	2
36	Copper deficiency anemia: review article. Annals of Hematology, 2018, 97, 1527-1534.	1.8	176

#	Article	IF	Citations
37	Clinical Features of Immune Checkpoint Inhibitor-Associated Autoimmune Hemolytic Anemia: A Series of 14 Cases. Blood, 2018, 132, 1037-1037.	1.4	1
38	Wide Variation in Duration of Anticoagulation after Catheter-Related Thrombosis: A Venous Thromboembolism Network US Multicenter Retrospective Cohort Study. Blood, 2018, 132, 1248-1248.	1.4	11
39	Hematologic and Thromboembolic Complications of Cancer and Their Treatment. , 2018, , .		O
40	The unusual nutritional and toxin-related underproduction anemias: approaching the riddle beyond iron, cobalamin, and folate. Discovery Medicine, 2018, 25, 67-74.	0.5	0
41	Copper deficiencyâ€related bone marrow changes secondary to longâ€term total parenteral nutrition. Clinical Case Reports (discontinued), 2017, 5, 195-196.	0.5	8
42	Performance of 4T score and heparin–platelet factor 4 antibody in the diagnosis of heparin-induced thrombocytopenia (HIT) in cancer. Journal of Thrombosis and Thrombolysis, 2017, 44, 261-266.	2.1	5
43	Risk of intracranial hemorrhage associated with therapeutic anticoagulation for venous thromboembolism in cancer patients: a systematic review and meta-analysis. Journal of Thrombosis and Thrombolysis, 2017, 43, 233-240.	2.1	13
44	Frequency of venous thromboembolism events during acute inpatient rehabilitation in a comprehensive cancer centre. Journal of Rehabilitation Medicine, 2017, 49, 758-764.	1.1	3
45	Rasburicase-Induced Methemoglobinemia in a Patient with Glucose-6- Phosphate Dehydrogenase Deficiency. Current Drug Safety, 2017, 12, 13-18.	0.6	13
46	Pernicious Anemia: Fundamental and Practical Aspects in Diagnosis. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 15, 17-22.	1.0	11
47	Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2017, 14, 101-112.	1.0	0
48	Challenging clinical presentations of pernicious anemia. Discovery Medicine, 2017, 24, 107-115.	0.5	9
49	Performance of 4T score and HIT Antibody in the Diagnosis of Heparin-Induced Thrombocytopenia in Cancer Patients. American Journal of Clinical Pathology, 2016, 146, .	0.7	0
50	Outpatient thromboprophylaxis with low-molecular-weight heparin in solid tumors: Where do we stand today?. Journal of Thrombosis and Thrombolysis, 2016, 41, 539-540.	2.1	3
51	A meta-analysis of intracranial hemorrhage in patients with brain tumors receiving therapeutic anticoagulation: comment. Journal of Thrombosis and Haemostasis, 2016, 14, 2080-2081.	3.8	2
52	Successful treatment of aplastic anemia–paroxysmal nocturnal hemoglobinuria associated with eosinophilic fasciitis with matched unrelated donor allogeneic peripheral blood stem cell transplantation. Clinical Case Reports (discontinued), 2016, 4, 765-767.	0.5	3
53	Transdisciplinary Approach to Managing Hepatitis C Virus Infection in Patients at a Tertiary Care Cancer Center. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1185-1188.	4.9	2
54	Benefit and risk of primary thromboprophylaxis in ambulatory patients with advanced pancreatic cancer receiving chemotherapy. Blood Coagulation and Fibrinolysis, 2016, 27, 270-274.	1.0	32

#	Article	IF	CITATIONS
55	Comment on "Efficacy of Prophylactic Low-Molecular Weight Heparin for Ambulatory Patients With Advanced Pancreatic Cancer: Outcomes From the CONKO-004 Trial― Journal of Clinical Oncology, 2016, 34, 515-515.	1.6	3
56	Low- Molecular Weight Heparins (LMWH) Versus Vitamin K Antagonists (VKAs) in the Treatment and Secondary Prevention of Cancer-Associated Venous Thromboembolism (VTE): A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCTs). Blood, 2016, 128, 1180-1180.	1.4	4
57	Natural history of heparin-induced thrombocytopenia (HIT) in the cancer population Journal of Clinical Oncology, 2016, 34, e18134-e18134.	1.6	0
58	Outcomes of Venous Thromboembolism (VTE) Treatment in Thrombocytopenic Leukemic Patients. Blood, 2016, 128, 4964-4964.	1.4	0
59	Risk of Bleeding from Primary Thromboprophylaxis (PTP) in Patients with Solid Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT). Blood, 2016, 128, 3820-3820.	1.4	0
60	A Systematic Review and Meta-Analysis of Randomized Controlled Trials (RCT) in Ambulatory Thromboprophylaxis (ATP) in Patients with Lung Cancer Receiving Chemotherapy. Blood, 2016, 128, 3825-3825.	1.4	0
61	Cancer Associated Thrombosis: Focus on Prevention and Treatment of Venous Thromboembolism. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2016, , .	1.0	0
62	Vitamin B <sub>12</sub> deficiency – A 21st century perspective. Clinical Medicine, 2015, 15, 402.1-402.	1.9	2
63	Management of cancer-associated disseminated intravascular coagulation: guidance from the SSC of the ISTH: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 1351-1352.	3.8	1
64	Update on Edoxaban for the Prevention and Treatment of Thromboembolism: Clinical Applications Based on Current Evidence. Advances in Hematology, 2015, 2015, 1-19.	1.0	11
65	Thrombotic thrombocytopenic purpura in a patient with lenalidomide-responsive multiple myeloma. Annals of Hematology, 2015, 94, 1605-1607.	1.8	8
66	Autoimmune Myelofibrosis and Systemic Lupus Erythematosus in a Middle-Aged Male Presenting Only with Severe Anemia. Medicine (United States), 2015, 94, e741.	1.0	11
67	Prevention of venous thromboembolism in cancer outpatients: guidance from the SSC of the ISTH: comment. Journal of Thrombosis and Haemostasis, 2015, 13, 323-324.	3.8	2
68	Advances in mechanisms, diagnosis, and treatment of pernicious anemia. Discovery Medicine, 2015, 19, 159-68.	0.5	15
69	Clinical utility of apixaban in the prevention and treatment of venous thromboembolism: current evidence. Drug Design, Development and Therapy, 2014, 8, 2181.	4.3	4
70	Letter to the Editor. Journal of the Royal College of Physicians of Edinburgh, The, 2014, 44, 186-189.	0.6	0
71	JAK2 (V617F) Positive Latent Myeloproliferative Neoplasm Presenting with Splanchnic Vein Thrombosis. Indian Journal of Hematology and Blood Transfusion, 2014, 30, 4-8.	0.6	1
72	Pernicious Anemia With Spuriously Normal Vitamin B12 Level Might Be Misdiagnosed As Myelodysplastic Syndrome. Clinical Lymphoma, Myeloma and Leukemia, 2014, 14, e141-e143.	0.4	6

#	Article	IF	Citations
73	Management of challenging cases of patients with cancer-associated thrombosis including recurrent thrombosis and bleeding: guidance from the SSC of the ISTH: a rebuttal. Journal of Thrombosis and Haemostasis, 2014, 12, 115-116.	3.8	4
74	Presence of paroxysmal nocturnal hemoglobinuria clones does not exclude inherited bone marrow failure syndromes. European Journal of Haematology, 2014, 93, 171-171.	2.2	3
75	Differential Diagnoses of Macrocytic Anemia, Reticulocytosis and Low Serum Haptoglobin in Patients with Myelodysplastic Syndromes/Acute Leukemia: Comment on "Two Cases of Acute Erythroid Leukemia Presenting with Marked Macrocytic Anemia, Reticulocytosis and Hemolysis". Internal Medicine, 2014, 53. 77-77.	0.7	1
76	Thymoma Complicated by Acquired Amegakaryocytic Thrombocytopenia and Pure Red Cell Aplasia. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 1505-1509.	4.9	14
77	Incidence and Management of Hematological Toxicities Associated with Treatment of Hepatitis C Virus Infection in Cancer Patients. Blood, 2014, 124, 4126-4126.	1.4	1
78	Mortality from Cancer-Associated Venous Thromboembolism. Blood, 2014, 124, 4829-4829.	1.4	6
79	Correspondence. Journal of the National Comprehensive Cancer Network: JNCCN, 2014, 12, 451-452.	4.9	0
80	Benefit and Risk of Primary Thromboprophylaxis in Ambulatory Patients with Advanced Pancreatic Cancer Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Blood, 2014, 124, 4266-4266.	1.4	0
81	Efficacy of Therapeutic Dose Versus Prophylactic Dose of Anticoagulants in the Primary Prevention of Thrombotic Events in Ambulatory Patients with Solid Malignancies Receiving Chemotherapy: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Blood, 2014, 124, 4275-4275.	1.4	0
82	Sequencing of $t(2;7)$ Translocations Reveals a Consistent Breakpoint Linking CDK6 to the IGK Locus in Indolent B-Cell Neoplasia. Journal of Molecular Diagnostics, 2013, 15, 101-109.	2.8	8
83	Low–Molecular Weight Heparin Prophylaxis Should Not Be Recommended Even in Highly Selected Patients With Solid Cancer Receiving Outpatient Chemotherapy. Journal of Clinical Oncology, 2013, 31, 4380-4381.	1.6	4
84	Hypofibrinogenemia, dysfibrinogenemia or hypodysfibrinogenemia?. Blood Coagulation and Fibrinolysis, 2013, 24, 353-354.	1.0	0
85	The Timing of Thrombophilia Testing is Important: Comment on "Left Main Coronary Artery Thrombus Resulting from Combined Protein C and S Deficiency". Internal Medicine, 2013, 52, 695-695.	0.7	1
86	Prevention and Treatment of Venous Thromboembolism with New Oral Anticoagulants: A Practical Update for Clinicians. Thrombosis, 2013, 2013, 1-10.	1.4	11
87	Coadministration of telaprevir and transcatheter arterial chemoembolization in hepatitis C virus-associated hepatocellular carcinoma. World Journal of Hepatology, 2013, 5, 332.	2.0	2
88	Low molecular weight heparin or semuloparin should not be recommended for thromboprophylaxis in ambulatory solid cancer patients undergoing chemotherapy. Thrombosis Research, 2012, 130, 821-822.	1.7	1
89	Comments on "Essential Thrombocytosis and Antiphospholipid Antibody Syndrome Causing Chronic Budd-Chiari Syndrome― Indian Journal of Pediatrics, 2012, 79, 1533-1534.	0.8	1
90	Bleeding Risk in Thrombocytopenic Cancer Patients with Venous Thromboembolism (VTE) Receiving Anticoagulation. Blood, 2012, 120, 3408-3408.	1.4	6

#	Article	IF	CITATIONS
91	Use of Growth Factors in Treatment of Hepatitis C Viral Infection in Cancer Patients. Blood, 2012, 120, 4725-4725.	1.4	0
92	Leukocytosis may be seen in patients with undiagnosed myelopoliferative disorders, factitious leukocytosis and venous thromboembolism. Thrombosis Research, 2011, 127, 487.	1.7	1
93	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 187-190.	0.6	1
94	Many residents under-report their work hours. BMJ: British Medical Journal, 2011, 342, d2424-d2424.	2.3	0
95	Comments on "Desvenlafaxine as a possible cause of acquired hemophilia― General Hospital Psychiatry, 2011, 33, e11.	2.4	0
96	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2011, 41, 91-94.	0.6	0
97	Amniotic Fluid Embolism Complicated by Paradoxical Embolism and Disseminated Intravascular Coagulation. American Journal of Critical Care, 2010, 19, 379-382.	1.6	10
98	Letters to the editor. Journal of the Royal College of Physicians of Edinburgh, The, 2010, 40, 92-94.	0.6	1
99	Deep Vein Thrombosis Associated with the New Oral Contraceptive Yasmin®. Southern Medical Journal, 2009, 102, 985-986.	0.7	3
100	Bronchus-Associated Lymphoid Tissue Lymphomas. Southern Medical Journal, 2009, 102, 1229-1233.	0.7	17
101	Translocation (2;7)(p11.2;q22) in a newly diagnosed low-grade B-cell non-Hodgkin lymphoma. Cancer Genetics and Cytogenetics, 2008, 181, 65-66.	1.0	2
102	Rituximab Can Induce a Durable Response in Refractory Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia: Case Report and Review of the Literature. Clinical Leukemia, 2008, 2, 140-142.	0.2	0
103	Marantic Endocarditis and Disseminated Intravascular Coagulation With Systemic Emboli in Presentation of Pancreatic Cancer. Journal of Clinical Oncology, 2008, 26, 1383-1385.	1.6	27
104	Pattern of Consultation Referrals for Cytopenia Evaluations to a Hematologist at An Academic Medical Center: The Expanding Role of a Consultant Hematologist. Blood, 2008, 112, 4673-4673.	1.4	1
105	Therapy-related chronic myelomonocytic leukemia with unique chromosomal abnormalities: Monosomy 7 and t(12;17)(p13;q11.2). American Journal of Hematology, 2007, 82, 248-249.	4.1	7
106	Trisomies 3 and 18 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2007, 176, 175.	1.0	0
107	Amiodarone-Associated Bone Marrow Granulomas: A Report of 2 Cases and Review of the Literature. International Journal of Hematology, 2007, 85, 101-104.	1.6	16
108	Morphologic heterogeneity of acute promyelocytic leukemia: Therapy-related acute promyelocytic leukemia presenting with FAB-M2 morphology. American Journal of Hematology, 2006, 81, 475-476.	4.1	1

#	Article	IF	CITATIONS
109	Clopidogrel-associated thrombotic thrombocytopenic purpura presenting with coronary artery thrombosis. American Journal of Hematology, 2006, 81, 890-891.	4.1	6
110	The Prevalence of Second Malignancies and Autoimmune Diseases in Patients with Lymphoproliferative Disorders Blood, 2006, 108, 4608-4608.	1.4	0
111	Gastric Relapse of Solitary Bone Plasmacytoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 325-326.	1.3	3
112	Primary Thyroid Lymphoma Presenting With Stridor. American Journal of Clinical Oncology: Cancer Clinical Trials, 2005, 28, 531-533.	1.3	5
113	Trisomy 8 in a newly diagnosed chronic lymphocytic leukemia. Cancer Genetics and Cytogenetics, 2005, 156, 94-95.	1.0	3
114	Drug Insight: new antiemetics in the management of chemotherapy-induced nausea and vomiting. Nature Clinical Practice Oncology, 2005, 2, 196-201.	4.3	39
115	Rituximab is Effective in the Treatment of Refractory Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia. Southern Medical Journal, 2005, 98, 1227-1228.	0.7	2
116	Hematocrit-Driven Referrals for Measurement of RBC Mass. Is the Natural History of Polycythemia Vera Changing? Blood, 2005, 106, 4960-4960.	1.4	0
117	Amiodarone- Induced Bone Marrow Granulomas Blood, 2005, 106, 4317-4317.	1.4	0
118	A Co-ligand Complex Anchors Plasmodium falciparum Merozoites to the Erythrocyte Invasion Receptor Band 3. Journal of Biological Chemistry, 2004, 279, 5765-5771.	3.4	91
119	Difficult Diagnostic and Therapeutic Cases. Journal of Clinical Oncology, 2004, 22, 953-954.	1.6	12
120	Difficult Diagnostic and Therapeutic Cases. Journal of Clinical Oncology, 2004, 22, 957-958.	1.6	2
121	Rituximab Is Effective in Refractory Adult Immune Thrombocytopenic Purpura Associated with Chronic Lymphocytic Leukemia Blood, 2004, 104, 3952-3952.	1.4	0
122	Uncommon Hematologic Malignancies. Journal of Clinical Oncology, 2003, 21, 4249-4251.	1.6	1
123	Uncommon Presentations of Malignancies. Journal of Clinical Oncology, 2003, 21, 2995-2996.	1.6	8
124	Uncommon Presentations of Malignancies. Journal of Clinical Oncology, 2003, 21, 2993-2995.	1.6	9
125	Possible Association between Hairy Cell Leukemia and Behçet's Disease. Southern Medical Journal, 2003, 96, 323-324.	0.7	5
126	Unfavorable Therapeutic Index of Cisplatin/Gemcitabine/Vinorelbine in Advanced nonâ€"small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 4, 47-51.	2.6	6

## THEIN HLAING OO

#	Article	IF	CITATIONS
127	Unusual Presentations of Lymphoma. Journal of Clinical Oncology, 2002, 20, 1942-1943.	1.6	3
128	Adrenal Hemorrhage Secondary to Metastasis from Lung Cancer. Clinical Lung Cancer, 2002, 4, 183-185.	2.6	11